ABCB1 Gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421C > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics

Pharmazie

Volumn 68, Issue 2, 2013, Pages 129-134

  Zhou, Quan ^a   Ruan, Zou Rong ^a   Yuan, Hong ^a   Xu, Dong Hang ^a   Zeng, Su ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; ROSUVASTATIN; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; CARRIER PROTEIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TUMOR PROTEIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; GENE MUTATION; GENOTYPING TECHNIQUE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; ASIAN; CONTROLLED CLINICAL TRIAL; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MALE; METABOLISM; POLYMERASE CHAIN REACTION; SEXUAL DEVELOPMENT;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; FEMALE; FLUOROBENZENES; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDICATORS AND REAGENTS; MALE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; SEX CHARACTERISTICS; SULFONAMIDES; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875830097     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2693     Document Type: Article

References (27)

1. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD, Samani NJ, Nixon J, Hall AS, Balmforth AJ; SPACE ROCKET Trial Group (2010) Hepaticmetabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 3: 276-285.
2. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83: 251-257.
3. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55: 94-99.
4. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478.
5. Hua WJ, Fang HJ, Hua WX (2012) Transepithelial transport of rosuvastatin and effect of ursolic acid on its transport in Caco-2 monolayers. Eur J Drug Metab Pharmacokinet 37: 225-231.
6. Hua WJ, Hua WX, Fang HJ (2012) The Role of OATP1B1 and BCRP in Pharmacokinetics and DDI of novel statins. Cardiovasc Ther 30: e234-241.
7. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86: 197-203.
8. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M (2009) No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 68: 207-213.
9. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
10. Kim KA, Joo HJ, Park JY (2010) ABCG2 polymorphisms, 34G >A and 421C >A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther 35: 705-712.
11. Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36: 2014-2023.
12. Kostapanos MS, Milionis HJ, Elisaf MS (2010) Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 10: 11-28.
13. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78: 330-341.
14. Liyue Hu, Yi W, Scott G (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34: 738-742.
15. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, Hidalgo IJ (2011) Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39: 1196-1202.
16. Li Y, Jiang X, Lan K, Jiang Q (2009) Comparative single- and multipledose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. Eur J Drug Metab Pharmacokinet 34: 221-227.
17. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ (2002) No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 42: 1116-1121.
18. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol Ther 75: 415-421.
19. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440.
20. Niemi M, Pasanen MK, Neuvonen PJ (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80: 356-366.
21. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82: 726-733.
22. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76: 167-177.
23. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK (2010) ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 87: 558-562.
24. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276: 35669-35675.
25. Xu DH, Ruan ZR, Zhou Q, Yuan H, Jiang B (2006) Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 20: 2369-2375.
26. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, Sun ZQ (2007) Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28: 1693-1697.
27. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH (2006) Role of BCRP 421C >A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373: 99-103.